Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report

Anaplastic thyroid cancer represents a rare, highly aggressive form of thyroid cancer with a poor prognosis and an overall survival ranging from 5 to 12 months. Unfortunately, treatment options remain limited, even for patients with a targetable driver mutation. Here, we present a case of a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroloff, Maxwell J, Holz, Josefin-Beate, Stern, Omer, Shepherd, Christopher J, Morrow, Michelle, Kayitalire, Louis, Wong, Deborah J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540849/
https://www.ncbi.nlm.nih.gov/pubmed/36202556
http://dx.doi.org/10.1136/jitc-2022-005225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540849/
https://www.ncbi.nlm.nih.gov/pubmed/36202556
http://dx.doi.org/10.1136/jitc-2022-005225

Ejemplares similares